NRXP - NRx Pharmaceuticals, Inc.

NasdaqGM - NasdaqGM Real-time price. Currency in USD

NRx Pharmaceuticals, Inc.

1201 Orange Street
Suite 600
Wilmington, DE 19801
United States
(484) 254-6134

Full-time employees

Key executives

NameTitlePayExercisedYear born
Mr. Stephen H. Willard Esq.CEO & Director501.19kN/A1961
Dr. Jonathan C. Javitt M.D., M.P.H.Co-Founder, Chief Scientist Officer & Director926.01kN/A1957
Dr. Seth L. Van Voorhees Ph.D.CFO & Treasurer399.96kN/A1961
Mr. Riccardo Panicucci Ph.D.Chief Technology Officer220kN/A1962
Suzanne MessereInvestor RelationsN/AN/AN/A
Dr. Michael KunzGen. Counsel & Corp. Sec.N/AN/A1965
Dr. Philip T. Lavin Ph.D.Chief MethodologistN/AN/A1947
Dr. Dennis K. McBride Ph.D.Chief Strategy Officer & Sr. ScientistN/AN/AN/A
Mr. Matthew Patrick DuffyChief Bus. OfficerN/AN/A1963
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics that is in phase IIb/III clinical trials for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.

Corporate governance

NRx Pharmaceuticals, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.